10-Q: Apyx Medical Q1 2026 Financial Results

Apyx Medical reports a 32.4% increase in Q1 2026 revenue to $12.5 million, driven by strong growth in its Surgical Aesthetics segment.

Summary

• Total revenue for Q1 2026 was $12.5 million, a 32.4% increase compared to $9.4 million in Q1 2025.
• Surgical Aesthetics segment revenue grew 36.1% to $10.7 million, supported by the commercial launch of the AYON Body Contouring System.
• Net loss narrowed to $2.1 million in Q1 2026 from $4.2 million in Q1 2025.
• Cash and cash equivalents stood at $31.1 million as of March 31, 2026.
• The company maintains a $37.5 million term loan with Perceptive Credit Holdings IV, LP.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to strong revenue growth and improved margins, though the ongoing net losses and potential for future dilution temper the outlook.

Positives

• Significant revenue growth of 32.4% year-over-year.
• Gross margin improved to 63.5% from 60.1% in the prior year period.
• Operating loss reduced by approximately $2.1 million compared to Q1 2025.
• Successful commercial launch of the AYON Body Contouring System.
• International sales grew 62.9%, representing 35.1% of total revenue.

Negatives

• Continued net losses and negative cash flow from operations.
• Increased reliance on international markets and potential exposure to tariffs.
• Higher salary and related costs due to increased headcount and benefits.
• Ongoing legal expenses related to product liability litigation.

Risks

• Uncertainty regarding the impact of GLP-1 weight loss drugs on the aesthetic surgery market.
• Potential for additional product liability claims and litigation costs.
• Requirement to meet specific revenue and operating expense covenants under the Perceptive Credit Agreement.
• Dependence on third-party suppliers and potential supply chain disruptions.
• Risk that additional capital may be required, leading to shareholder dilution.

Future Outlook

The company anticipates receiving FDA clearance for the AYON label expansion to include power liposuction in the second quarter of 2026. Management expects continued losses in the near term and plans to fund operations through existing cash, product sales, and potential future financing.

Management Comments

• Management believes the use of GLP-1 drugs may create a tailwind for Renuvion products due to the resulting skin laxity requiring body contouring.
• The company expects OEM segment revenue to decrease over time as it shifts focus toward the Surgical Aesthetics segment.

Industry Context

StockSavvy.ai notes that Apyx Medical is navigating a shifting aesthetic market where GLP-1 adoption is creating both uncertainty and new demand for body contouring solutions. The company's pivot toward the AYON system aligns with industry trends favoring multi-functional, minimally invasive surgical platforms.

Comparison to Industry Standards

• Revenue growth of 32.4% outperforms many traditional medical device peers in the aesthetic space.
• Gross margin of 63.5% is competitive with other specialized surgical device manufacturers.
• The company's reliance on a single-use handpiece model is a standard, high-margin strategy similar to other aesthetic device companies.

Legal Proceedings

• The company is defending multiple product liability lawsuits related to the use of its Helium Plasma Platform Technology.
• Estimated loss range for certain product liability matters is between $1.625 million and $1.825 million.

Related Party Transactions

• The company has a joint venture with a Chinese supplier who also acts as a vendor; purchases from this supplier totaled $613,000 in Q1 2026.
• Certain relatives of the Managing Director of Apyx Bulgaria are employed by the company.

Stakeholder Impact

• Shareholders face potential dilution if additional equity is raised.
• Creditors are protected by specific financial covenants and a $3 million minimum cash balance requirement.
• Customers benefit from the expanded product portfolio including the AYON system.

Next Steps

• Anticipated FDA clearance for AYON label expansion in Q2 2026.
• Continued monitoring of financial covenants under the Perceptive Credit Agreement.
• Ongoing defense of product liability litigation.

Key Dates

Recommendation

While the company shows strong growth and improved operational efficiency, the ongoing net losses, legal liabilities, and potential for shareholder dilution warrant a cautious hold position until the company demonstrates a clear path to profitability.

Keywords

Apyx Medical, Surgical Aesthetics, Renuvion, AYON Body Contouring, Medical Devices, Helium Plasma Technology, 10-Q